Molecular Diagnosis of Sexually-transmitted Chlamydia trachomatis in the United States by Harkins, April & Erik, Munson
Marquette University
e-Publications@Marquette
Clinical Lab Sciences Faculty Research and
Publications Clinical Lab Sciences, Department of
1-1-2011
Molecular Diagnosis of Sexually-transmitted
Chlamydia trachomatis in the United States
April Harkins
Marquette University, april.harkins@marquette.edu
Munson Erik
University of Wisconsin - Milwaukee
Published version. ISRN Obstetrics and Gynecology, Vol. 2011, (2011). DOI: 10.5402/2011/279149.
© 2011 Hindawi Publishing Corporation. Used with permission.
International Scholarly Research Network
ISRN Obstetrics and Gynecology
Volume 2011, Article ID 279149, 17 pages
doi:10.5402/2011/279149
Review Article
Molecular Diagnosis of Sexually Transmitted
Chlamydia trachomatis in the United States
April L. Harkins1 and Erik Munson2, 3
1Department of Clinical Laboratory Science, Marquette University, Milwaukee, WI 53233, USA
2Wheaton Franciscan Laboratory, 11020 West Plank Court, Suite 100, Wauwatosa, WI 53226, USA
3College of Health Sciences, University of Wisconsin—Milwaukee, Milwaukee, WI 53201, USA
Correspondence should be addressed to Erik Munson, erik.munson@wfhc.org
Received 4 March 2011; Accepted 27 April 2011
Academic Editor: E. Petru
Copyright © 2011 A. L. Harkins and E. Munson. This is an open access article distributed under the Creative Commons
Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is
properly cited.
Chlamydia, with its Chlamydia trachomatis etiology, is the most common bacterial sexually transmitted infection in the United
States and is often transmitted via asymptomatic individuals. This review summarizes traditional and molecular-based diagnostic
modalities specific to C. trachomatis. Several commercially available, FDA-approved molecular methods to diagnose urogenital C.
trachomatis infection include nucleic acid hybridization, signal amplification, polymerase chain reaction, strand displacement
amplification, and transcription-mediated amplification. Molecular-based methods are rapid and reliable genital specimen
screening measures, especially when applied to areas of high disease prevalence. However, clinical and analytical sensitivity for
some commercial systems decreases dramatically when testing urine samples. In vitro experiments and clinical data suggest that
transcription-mediated amplification has greater analytical sensitivity than the other molecular-basedmethods currently available.
This diﬀerence may be further exhibited in testing of extragenital specimens from at-risk patient demographics. The development
of future molecular testing could address conundrums associated with confirmatory testing, medicolegal testing, and test of cure.
1. Ecology and Epidemiology of
Urogenital Chlamydia
1.1. Prevalence and Transmission. Since becoming a nation-
ally notifiable disease in the United States in 1995, chlamydia
has experienced consistent annual increases (averaging 5.8%)
to its 2009 prevalence rate of 409.2 per 100,000 inhabitants
(Figure 1(a)), making it the most common bacterial sexually
transmitted infection (STI) in this country [1]. Data from
the United States Centers for Disease Control and Prevention
(CDC) have revealed that chlamydia rates are highest in
late adolescents and young adults ([1], Figure 1(b)). African
Americans and Native Americans demonstrate higher rates
of chlamydia compared to other races or ethnicities (Fig-
ure 1(c)).
Sexually active asymptomatic populations have been
implicated in widespread transmission of the Chlamydia
trachomatis etiology. Selective screening of sexually active
women has yielded infection rates ranging from 8% to 40%
(typical mean of 15%, [2]), while approximately 10% of
sexually active asymptomatic males are infected [3, 4]. In
contrast to Neisseria gonorrhoeae infection in which most
patients develop symptoms and seek care promptly, Hook
et al. [5] reported that most females and males with C.
trachomatis infection were asymptomatic or mildly symp-
tomatic upon clinical presentation. Diagnosis was largely
on the basis of screening or having a symptomatic contact.
Further evidence that chlamydia is a prevalent disease rather
than an incident disease comes from extrapolations of STI
agent acquisition rates. While past studies have suggested
that gonorrhea sexual transmission can be more eﬃcient
than chlamydia transmission [6, 7], recent data utilizing C.
trachomatis molecular diagnostics report less of a disparity
between transmission rates [8]. Katz et al. [7] estimated a
0.32–0.39 chlamydia transmission rate when using culture
as a detection modality, while Quinn et al. [8] estimated
this rate to be approximately 0.68 when utilizing molecular
diagnostics. It is important to note that these extrapolations
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Figure 1: Epidemiology of chlamydia in the United States, summarized in terms of annual incidence rates (a), prevalence within arbitrary
age groups (b), and race/ethnicity distribution (c). Solid bars represent male gender and shaded bars represent female gender. Data are
adapted from [1].
were performed on the basis of historical average frequency
of intercourse between pairs, rather than single sexual
encounter, which provided the basis for studies of gonorrhea
transmission [9, 10].
1.2. Urogenital Chlamydia in Males. Ocular trachoma, lym-
phogranuloma venereum, perinatal infections, and adult
oculogenital disease outline four clinical categories of C.
trachomatis infections described by Stamm et al. [11]. We
briefly summarize selected important clinical manifestations
of urogenital disease as they pertain to subsequent laboratory
diagnosis of the disease etiology. C. trachomatis is thought
to be responsible for 30–50% of cases of nongonococcal
urethritis (NGU) inmen. Appropriate laboratory diagnostics
in male urethritis are important for at least four reasons:
(1) symptom overlap with clinical gonococcal urethritis and
NGU may exist (Table 1); (2) prevalence of NGU in the
United States exceeds that of gonococcal urethritis [2]; (3) C.
trachomatismay be detected from a substantial proportion of
patients with gonococcal urethritis [12], and concomitantly,
(4) dually infected males who are treated solely for gonococ-
cal urethritis are likely to develop post gonococcal urethritis,
manifested as persistence or recurrence. Risk factors for
chlamydial urethritis have included heterosexual orientation,
African American race, and age younger than 20 years [13].
1.3. Urogenital Chlamydia in Females. Mucopurulent cer-
vicitis caused by C. trachomatis is said to be the female
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Table 1: Factors that attempt to distinguish male nongonococcal urethritis from those cases caused by Neisseria gonorrhoeae.
Factor Gonococcal urethritis Nongonococcal urethritis Reference(s)
Typical incubation period 2–5 days 7–14 days [14, 15]
Range of symptom onset 1–10 days 2–35 days [14, 15]
Frank purulent discharge (% of cases) 75 11–33 [16, 17]
Mucopurulent discharge (% of cases) 25 50 [16, 17]
Clear or moderately viscid discharge (% of cases) 4 10–50 [16, 17]
Dysuria (% of cases) 73–88 53–75 [16, 18]
Combination of dysuria and discharge (% of cases) 71 38 [16]
counterpart of male NGU, as approximately 70% of women
are asymptomatic or experience only mild symptoms such as
bleeding, discharge, mild abdominal pain, and dysuria. Being
a sex partner of a male with NGU or gonococcal urethritis
has been reported to confer an infection risk of greater
than 30% [2, 12]. Additional factors such as younger age,
African American race, unmarried status, new or multiple
sex partners, oral contraceptive use, and residence in the
southeast United States promote higher rates of chlamydia
in sexually active females [2, 19].
Symptoms relative to mucopurulent cervicitis can also
characterize conditions such as cystitis and vaginitis. As such,
diagnosis of chlamydia may be masked by diagnosis and
treatment of concomitant N. gonorrhoeae and Trichomonas
vaginalis infection. A Milwaukee, Wisconsin laboratory used
highly sensitive molecular methods for the detection of
these agents [20, 21] to determine the STI profile of 272
female healthcare encounters that proved to be positive for
at least one STI. In this populace that ranks second in the
United States in both chlamydia and gonorrhea prevalence
[1], 17% of patients with detectable C. trachomatis-specific
nucleic acid had concomitant N. gonorrhoeae and/or T.
vaginalis nucleic acid detection [22]. The development of
accurate laboratory diagnostics for C. trachomatis bears
additional importance in light of data associating chlamydial
cervicitis with acquisition of human immunodeficiency virus
in women [23, 24].
2. Selected Nonmolecular Means of
Laboratory Diagnosis
Formany years, the accepted gold standard forC. trachomatis
detection was culture. Culturing techniques in McCoy
cell lines are rather complex and time consuming, with
the necessity for experienced laboratory technologists for
accurate follow-up staining and microscopy. Sensitivity of
culture methodology is much less compared to nucleic acid
amplification testing (NAAT), allowing for false negative
results to potentiate the spread of infection [25–28].
In 2002, the CDC recommended routine laboratory
screening for individuals at high risk of acquiring STIs
[29], particularly with eﬀective treatment regimens for C.
trachomatis andN. gonorrhoeae being both accessible and in-
expensive. The detection of C. trachomatis by rapid screen-
ing or point-of-care methods includes nonamplification
methods such as direct fluorescent antibody testing (DFA),
optical immunoassay (OIA), and rapid solid-phase enzyme
immunoassay (EIA). These methods were developed to pro-
vide a level of service to the community, enabling clinicians
to begin treating patients on the day of the detection (a “test
and treat” strategy) and consequently reducing the risk of
inflammatory sequelae and the spread of infection. This re-
presents a significant public health issue as 20% of patients
that are diagnosed with C. trachomatis do not return to
follow-up medical attention within a one-month interval,
with 3% of these patients subsequently developing PID
within this timeframe [30, 31].
The DFA procedure begins with fixing epithelial cells
from the conjunctiva, urethra, or cervix to a microscope
slide. Monoclonal antibodies specific for C. trachomatis
major outer membrane protein, conjugated with fluorescein
isothiocyanate (FITC), bind to intracellular inclusions if
the organism is present. The DFA procedure is considered
rapid or point-of-care testing due to its capacity to be
performed within 30 minutes, although expertise in reading
fluorescence microscopy is required and the method exhibits
low sensitivity when compared to NAAT. In one study,
Boyadzhyan et al. [32] reported that C. trachomatis culture
and DFA failed to detect 28% and 0%, respectively, of
specimens determined to be positive by NAAT.
The rapid OIA consists of an optical reading, which has
a very subjective color change as its basis. C. trachomatis
antigens present within specimens will react with specific
antibodies impregnated on a silicon wafer. The Biostar OIA
has been evaluated in urogenital specimens from women at
an STI clinic [25, 26]. Swain et al. [25] evaluated 1,385
women for C. trachomatis infection using the DFA, OIA,
and culture methods. Sensitivity and specificity for testing
methods were 73.6% and 99.9%, respectively, for DFA,
64.2% and 99.1% for OIA, 56.1% and 100% for culture,
and 95.3% and 99.8% for PCR. During the study, these
modalities were referenced against an expanded gold stan-
dard, which included NAAT testing if the culture was neg-
ative. The researchers concluded that a universal screening
program utilizing rapid testing for laboratory diagnosis of
C. trachomatis was not recommended. The decision analysis
the investigators provided did show that the poorly sensitive
rapid testing is potentially useful in clinics where patients do
not comply to follow-up treatments.
The true sensitivity of nonmolecular diagnostic testing
for C. trachomatis is predicated on the quality of the
reference standard. Those assays that are compared to culture
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or analogous rapid or point-of-care testing in terms of
sensitivity could demonstrate falsely elevated performance
characteristics. Bandea and colleagues [27] showed the
sensitivity of the Biostar Chlamydia OIA as 78.6% and
specificity as 97.2% with culture as the reference standard.
This is in contrast to another study [33], utilizing a reference
standard based on concordant results from two NAAT
modalities that reported sensitivity and specificity for the
Biostar OIA at 59.4% and 98.4%, respectively. Moreover, C.
trachomatis detection by point-of-care EIA methodology has
also shown to have decreased sensitivity compared to NAAT.
Van Dommelen et al. [34] demonstrated that sensitivity
of three rapid EIAs was extremely low (17.1% to 25%)
compared to NAAT.
Using a test with a low sensitivity may result in patients
being falsely reassured by a negative test result, potentiating
spread of infection and progression of disease to PID or
other infertility sequelae [35]. In assessing the proper rapid
test to use for C. trachomatis diagnosis, the World Health
Organization has recently released the ASSURED criteria
for rapid STI assays; aﬀordable, sensitive, specific, user-
friendly, rapid and robust, equipment-free and deliverable
[35]. The optimal context for utilization of point-of-care
testing is reflexive followup with NAAT. Until sensitivity of
rapid point-of-care testing improves, one has to be very
cautious in using nonamplificationmethods alone, especially
in low-prevalence populations in which assays yield positive
predictive value of <90%.
3. Molecular Means of Laboratory Diagnosis
3.1. Commercial Nucleic Acid Hybridization. Nucleic acid
hybridization technologies employ oligonucleotide sequ-
ences that are designed to anneal to complementary sequ-
ences within target nucleic acid. Because of analytical sensi-
tivity issues inherent to nucleic acid hybridization, this para-
digm is generally reserved for clinical conditions with a high
organism burden [36]. In a study set of 201 cervical speci-
mens, LeBar et al. [37] determined the sensitivity of PACE
2 (Gen-Probe, Incorporated, San Diego, Calif, USA) for the
detection of C. trachomatis-specific 16S ribosomal RNA to
be 82.8% compared to a C. trachomatis cell culture reference.
78.0% assay sensitivity was reported in an additional study
of 217 cervical specimens [38]. Specificity of C. trachomatis-
specific PACE 2 was documented at 98.8–99.4% [37, 38].
In a study of male urethral specimens, Kluytmans et
al. [39] developed two oﬀ-label modifications to the C.
trachomatis PACE 2 assay that yielded assay sensitivity of
89.5%. Within 398 endocervical specimens, Limberger et
al. [40] reported that 19 of 20 C. trachomatis cell culture-
positive specimens were also PACE 2-positive. This high
frequency of concordance was not noted with specimens
that were mailed to the laboratory for analogous nucleic
acid hybridization for N. gonorrhoeae and may therefore
reflect the susceptibility of the latter STI agent to conditions
of specimen transport. This may be particularly true in
light of past data reporting a 99.4% N. gonorrhoeae-specific
PACE 2 sensitivity in a sampling of 436 cervical or urethral
swabs [41]. Taken together, these data begin to portend that
decreased sensitivity of nucleic acid hybridization testing for
C. trachomatis may be linked with a suboptimal cell culture
reference method, rather being limited by mitigating factors
such as specimen transport.
3.2. Commercial Signal Amplification. Neither target nor
oligonucleotide probe nucleic acid concentrations change in
the signal amplification paradigm. Instead, the concentration
of reporter molecules is increased at the site of target/probe
hybridization [36]. Commercially available signal amplifica-
tion methods detecting C. trachomatis alone, or in concert
with N. gonorrhoeae, utilize hybrid capture technology
(Hybrid Capture II (HC2) product line; Digene Corpora-
tion (QIAGEN), Gaithersburg, Md, USA). Targets for C.
trachomatis the detection include specific chromosomal and
cryptic plasmid sequences. Schachter et al. [42] evaluated
the HC2 CT-ID test using a combined C. trachomatis cell
culture and direct fluorescent antibody reference method
and demonstrated 97.7% sensitivity for detection of C. tra-
chomatis from endocervical specimens. Within the 129 true-
positive specimens, only 114 (88.4%) yielded a positive C.
trachomatis culture result. The utilization of the antecedent
HC2 CT/GC test to screen for the presence of either N.
gonorrhoeae or C. trachomatis exhibited 95% sensitivity. A
two-center study [43] reported 96.6% sensitivity of the HC2
CT-ID test on endocervical specimens from high-risk female
populations in relation to a culture reference. However, upon
the adjudication of discrepancies with PCR, sensitivity of the
HC2 CT-ID test was 97.2% compared to a culture sensitivity
of 80.6%. Greater than 98% specificity was noted in both
studies [42, 43]. Modarress et al. [44] evaluated the HC2
CT/GC test using genital swab specimens collected for PACE
2 testing and demonstrated approximately 87% and 100%
sensitivity of PACE 2 and HC2 CT/GC, respectively, for
the detection of either C. trachomatis or N. gonorrhoeae,
although only the diﬀerence in C. trachomatis detection rate
was significant between the two modalities (P < 0.016).
3.3. Commercial Polymerase Chain Reaction (PCR). The
long-standing PCR [45, 46] DNA target amplification
method is the basis of the multiplex AMPLICOR CT/NG
product line (including the COBAS fully automated plat-
form), heretofore, referred to as AMP (Roche Molecular Sys-
tems, Incorporated, Branchburg, NJ). C. trachomatis target
for this assay is a 207-nucleotide sequence within a cryptic
plasmid that is highly conserved within all serotypes of the
organism. Livengood III and Wrenn [28] demonstrated a
disparity in the rate of C. trachomatis detection from endo-
cervical specimens by AMP (93.3%) versus C. trachomatis
culture (65.0%)—far greater than that disparity (3.7%)
observed for N. gonorrhoeae. A multicenter evaluation of
AMP yielded 89.2–89.7% sensitivity in the detection of
C. trachomatis target from female urine and endocervical
specimens, respectively, with 88.6–90.3% sensitivity derived
from male urethral and urine specimens when using an
infected patient standard [47]. Data from a European
study [48] demonstrated 92.0–98.0% AMP sensitivity from
male specimen sources and female endocervical specimens,
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Table 2: Performance characteristics of three commercially-available Chlamydia trachomatis molecular screening platforms per
manufacturer-provided data. Ranges reflect diﬀerences in performance characteristics between specimens collected from symptomatic and
asymptomatic individuals (when specified).
Commercial assay Gender Specimen
Performance indices
Sensitivity range (%) Specificity range (%)
AMPLICOR
Female
Endocervical 87.4–94.0 98.6
Urine 84.3–89.5 98.0–98.8
Male
Urethral 96.3–98.7 95.2–97.7
Urine 87.6–92.0 91.9–95.7
BD ProbeTec ET
Female
Endocervical 88.7–96.8 97.9–98.5
Urine 77.0–83.9 98.2–98.3
Male
Urethral 89.5–95.5 92.9–97.0
Urine 89.5–95.4 89.4–95.8
APTIMA Combo 2†
Female
Endocervical 92.4–98.4 96.7–98.8
Urine 93.8–96.8 98.8–99.0
Male
Urethral 94.6–96.4 96.9–98.4
Urine 96.3–98.5 98.4–98.8
†
APTIMA Combo 2 clinician-collected vaginal swab sensitivity range 96.5–96.7%, specificity range 96.4–97.2%; APTIMA Combo 2 patient-collected vaginal
swab sensitivity 98.4%, specificity 96.8%.
yet reported 82.5% sensitivity of C. trachomatis detection
from female urine specimens. The aforementioned studies
reported ≥98.4% specificity from all specimen sources [47,
48]. From a peripheral and foreshadowing sense, noteworthy
from the van Doornum et al. data [48] and an additional
study [49] was the apparent deficit of AMP to accurately
detect N. gonorrhoeae DNA from female urine specimens
(sensitivity values ranged from 64.8–66.7%). A summary
of manufacturer-published performance characteristics of
commercial NAAT on urine and endocervical/urethral speci-
mens described in this review is presented in Table 2 [50–52].
3.4. Commercial Strand Displacement Amplification (SDA).
A multiplex isothermal DNA target amplification method
[53] constitutes a leading diagnostic assay for the detection
of C. trachomatis in the United States (BD ProbeTec ET
C. trachomatis and N. gonorrhoeae amplified DNA assay
(heretofore referred to as ProbeTec); Becton, Dickinson and
Company, Sparks, Md, USA). In the context of C. trachoma-
tis, SDA targets the chlamydial cryptic plasmid—up to ten
copies of which can be found in each cell. A seven-center
evaluation [54] utilized C. trachomatis-specific cell culture,
DFA, and a since-defunct commercial ligase chain reaction to
determine infected patient status and related 92.5% ProbeTec
sensitivity in the detection of C. trachomatis from male
urethral swabs. Sensitivity of the assay onmale urine (93.1%)
exceeded that of the commercial PCR assay described
previously [47]. In spite of reasonable sensitivity for the
detection of C. trachomatis derived from endocervical swabs
(92.8%), assay of female urine yielded only 80.5% sensitivity.
However, combined percentage specificity of the assay was
high among both genders (97.3%, [54]) yet it is noteworthy
that the specificity of urine specimens among 124 symp-
tomatic males with positive infection status was 92.6%. The
analogous value for urethral specimens was 95.9%.
3.5. Commercial Transcription-Mediated Amplification
(TMA). A third commonly utilized nucleic acid target am-
plificationmethod in the United States for the detection ofC.
trachomatis has its basis in isothermal TMA [55]. A 109-fold
rate of RNA amplification is reported to occur in two hours
via TMA [56] in contrast to a 106-fold DNA amplification
rate in three to four hours [46]. The multiplex Gen-Probe
APTIMA Combo 2 assay (heretofore referred to as AC2)
targets C. trachomatis-specific 23S ribosomal (r)RNA which
is present in high copy number. A seven-site evaluation
of 1391 females [21] demonstrated 94.2% C. trachomatis
assay sensitivity from endocervical specimens. Sensitivity
of C. trachomatis detection from female urine (94.7%) was
markedly higher than those values derived from AMP or
ProbeTec. In this study, specificity of AC2 ranged from 97.6%
for endocervical specimens to 98.9% for urine specimens.
In response to commercial systems, especially AMP, demon-
strating nonspecific amplification in the context of N.
gonorrhoeae NAAT [57–59], direct challenges of AC2 with
nonpathogenic Neisseria spp. and chlamydiae other than C.
trachomatis failed to result in amplification [60]. Further-
more, Lowe et al. [61] noted a 10% greater sensitivity of AC2
than AMP for detecting C. trachomatis in urine specimens.
4. Comparison of Performance Characteristics
of Commercial NAAT
4.1. Analytical Sensitivity. The increased clinical sensitivity
exhibited by AC2 may reflect a phenomenon specific to
TMA. A 34.6% serum detection rate of hepatitis C virus
(HCV)-specific nucleic acid via TMA was demonstrated in
disease relapse patients who had apparent virus clearance
according to conventional qualitative and quantitative PCR
assays [62]. Sarrazin et al. [63] reported a 51.1% residual
serum HCV detection rate by TMA versus conventional
6 ISRN Obstetrics and Gynecology
qualitative PCR assays, including a 36.4% rate compared
to an assay with a lower detection limit of 100 nucleic
acid copies/mL. Chernesky et al. [64] prepared mock swab
specimens containing propagated C. trachomatis elementary
bodies and showed that the analytical sensitivity of AC2 was
1000-fold greater than that of ProbeTec and 10-fold greater
than that of AMP. AC2 exhibited 100-fold greater sensitivity
than the two comparators with analogous mock urine
specimens. Ikeda-Dantsuji et al. [65] dispensed standardized
amounts of C. trachomatis elementary bodies into mock
specimens and showed within a subsequent dilution series
that AC2 analytical sensitivity was 1000-fold greater than
that of AMP. Wood et al. [66] demonstrated a lower
limit of detection of N. gonorrhoeae via AC2 (102 colony
forming units/mL) than that rendered by ProbeTec or AMP
(≥103 colony forming units/mL).
4.2. Role of Endogenous Specimen Inhibitors. A second con-
tributory factor to the purported increased analytical sen-
sitivity of AC2 is decreased susceptibility of the assay
to endogenous inhibitors of nucleic acid amplification.
Substances suggested to inhibit C. trachomatis NAAT have
included hemoglobin, low-pH cervical mucosa, β-chorionic
gonadotropin, urine crystals, and urine nitrites [67–69].
Analysis of the first-generation Gen-Probe Chlamydia TMA
assay using 388 urine specimens revealed an 11.9% rate
of amplification inhibition [67]. This figure exceeded that
of commercial PCR by nearly 5%. Introduction of the
organism-specific nucleic acid target capture protocol with
concomitant washing and aspiration (under the auspices of
second-generation AC2) has negated this inhibitory eﬀect.
Ikeda-Dantsuji et al. [65] subjected mock AC2 and AMP
specimens containing C. trachomatis near the AMP lower
limit of detection to increasing concentrations of phosphate
and iron and demonstrated that both chemicals only pro-
moted an inhibitory eﬀect on AMP performance. Gaydos
et al. [70] reported 75 true-positive C. trachomatis screens
from 506 total female and male urine specimens via AC2
plus an additional four specimens that also tested positive by
a TMA-based assay targeting an alternative sequence. These
data compared favorably to the 72 true-positive results from
the same study set identified by ProbeTec.
In an ex vivo study [64], rates of C. trachomatis nucleic
acid amplification inhibition for AC2 (1.3–1.7%) were fairly
equivalent to that of ProbeTec (2.0%) for female genital
swabs but were far less than those derived from AMP
(10.4–12.8%). Rates of amplification inhibition from urine
specimens were exceedingly high for ProbeTec and AMP
(27.2% and 12.1%, resp.), when compared to AC2 (0.3%).
Modifications to the ProbeTec urine collection and trans-
port system have addressed issues related to amplification
inhibition [71]. A recent Canadian study [72] reported
98.0% ProbeTec sensitivity in the detection of C. trachomatis
from 500 urine specimens compared to AC2 sensitivity of
99.0%. Analogous sensitivity indices for the detection of
N. gonorrhoeae were 95.8% for ProbeTec and 100% for
AC2. Improved performance of NAAT on urine specimens,
and subsequent overall clinical acceptance of this specimen
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Figure 2: Chlamydia rates per 100,000 inhabitants by gender in the
United States from 2005–2009. Filled bars represent male gender
and shaded bars represent female gender. Data are adapted from [1].
source, has been cited by the CDC [1] as a factor responsible
for a larger increase in C. trachomatis detection in males in
the United States from 2005–2009 (37.6%) than that increase
observed in females (20.3%; Figure 2).
4.3. Extragenital Specimen Sources. C. trachomatis has a trop-
ism for columnar epithelial cells [73]. This cell type consti-
tutes the vagina of prepubescent girls and is replaced with
stratified squamous epithelium upon increased concentra-
tions of estrogen at puberty [74]. In spite of this histological
diﬀerence, C. trachomatis has eﬃciently been recovered from
adult vaginal specimens, further promulgating the high
analytical sensitivity of NAAT. Schachter et al. [75] utilized
a variety of commercial NAAT modalities to demonstrate
that vaginal swabs had nearly equivalent sensitivity to that
of endocervical swabs for the detection of C. trachomatis,
with approximately 12% more sensitivity than first-catch
urine. Moreover, patient-collected vaginal swabs had equal
sensitivity as clinician-collected vaginal swabs. A multicenter
investigation of AC2 performance for C. trachomatis on
vaginal swabs [76] revealed 96.6% and 96.7% sensitivity
on patient- and clinician-collected specimens, respectively,
extending previous findings [75]. Positive C. trachomatis
vaginal screening results were in 91% and 95% concordance
with those from endocervical and first-void urine collection,
respectively [76]. Sensitivity of C. trachomatis AMP from
a vaginal swab was 18–22% greater than that of a C.
trachomatis EIA [77]. C. trachomatis detection via ProbeTec
and AMP revealed equivalent sensitivity for both vaginal and
endocervical specimens [78]. In a study of C. trachomatis
detection via AC2, 98.6% of infected women were detected
via vaginal swab testing, compared to 89.9% and 81.2% from
endocervical swabs and first-void urine, respectively [64].
These AC2 specimen-specific percentages of detection were
statistically higher than analogous percentages generated by
ProbeTec and AMP (P = 0.001). In a limited data set (n =
25 determinations), our laboratory has demonstrated that
the transfer of 200-μL aliquots of vaginal saline suspensions
(originally designated for microscopic examination of vulvo-
vaginitis etiologies) into AC2 specimen transport tubes (lysis
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medium) results in the detection of C. trachomatis upon per-
formance of AC2 (E.Munson, unpublished observations). To
date, AC2 is the only commercially available modality that
has received an FDA indication for vaginal swab collections.
In a description of a potential role for NAAT in labora-
tory diagnosis of rectal chlamydia, Schachter et al. [79]
reported an ≥36.7% increase of sensitivity between NAAT
modalities and C. trachomatis culture (26.5% sensitivity).
In the same males who have sex with males (MSM) demo-
graphic, sensitivity ofC. trachomatis culture from pharyngeal
sites was 44.4%. This contrasted with NAAT modalities that
reported sensitivity of ≥66.7%. Ota et al. [80] reported
sensitivity of C. trachomatis culture and two NAAT modal-
ities from rectal specimens as being 21.1% and 94.7%,
respectively, from an MSM demographic. The same group
reported a significant proportion of pharyngeal detection of
C. trachomatis via NAAT in the face of a 0% culture-positive
rate. Using a rotating infected patient status, Bachmann et al.
[81] determinedC. trachomatis culture sensitivity to be 36.1–
45.7% from rectal swabs in a combined MSM and at-risk
female demographic.
Early data suggested PCR utility in the detection of
C. trachomatis from ocular specimens [82, 83], with one
report documenting a 26% increase in overall C. trachomatis
detection over that derived fromDFA [83]. Commercial PCR
additionally proved to have suﬃcient diagnostic capacity for
ocular chlamydia. Kowalski et al. [84] reported 88.1% sen-
sitivity and 100% specificity of AMP on adult conjunctival
specimens. Hammerschlag et al. [85] documented 92.3%
sensitivity of AMP derived from infant specimens. Studies
have also spoken to the utility of nasopharyngeal and nasal
discharge specimens in both diagnosis and predictive value
of antimicrobial therapy in the context of chlamydial con-
junctivitis [85, 86]. Children with a positive C. trachomatis
AMP result on a nasal discharge at the commencement
of macrolide therapy had an odds ratio of 5.15 to yield a
positive AMP result from an ocular specimen two months
after therapy when compared to children with a negative
AMP result from nasal discharge at baseline [86].
Comparisons of commercial NAAT modalities for the
detection of C. trachomatis from non-FDA-indicated extra-
genital sources have ensued. Schachter et al. [76] reported
that 32.9% of C. trachomatis-positive vaginal screening
results obtained by AC2 could not be replicated via ProbeTec
analysis of a corresponding first-void urine specimen. 64.7%
sensitivity of AMP for the detection of C. trachomatis has
been demonstrated from rectal specimens when compared to
AC2 [80]. The same study reported 33.3% AMP sensitivity
for the detection of pharyngeal C. trachomatis using a
reference infected patient status in what turned out to be a
very low-incidence specimen source. Furthermore, AC2 was
30% and 33% more sensitive than ProbeTec in detection
of C. trachomatis nucleic acid from rectal and pharyngeal
sites, respectively. For diagnosis of rectal chlamydia using a
rotating infected patient status, Bachmann et al. [81] calcu-
lated sensitivity ranges of AMP, ProbeTec, and AC2 at 80.7–
95.5%, 92.2–100%, and 100%. Ota et al. [80] reported that
AC2 outperformed ProbeTec by 15–20% in an MSM demo-
graphic in terms of sensitivity from rectal and pharyngeal
specimens, respectively. In further support of this paradigm,
in studies of N. gonorrhoeae detection from pharyngeal and
rectal sites, Bachmann and colleagues [59, 81] determined
the performance of AMP to be inferior to that of ProbeTec
or AC2. In a study of an MSM demographic [87], of 86
pharyngeal and 99 rectal specimens that generated a positive
AC2 result, only 32.6% and 34.3% were positive by N.
gonorrhoeae culture, respectively. Of the 102 glans specimens
positive for N. gonorrhoeae by AC2, 96–100% of these results
were confirmed by secondary NAAT. In contrast, a higher
percentage of N. gonorrhoeae AMP-positive rectal swabs
were positive by N. gonorrhoeae culture when compared to
analogous AC2 data. Collectively, these findings challenge the
overall analytical sensitivity of AMP for the detection of STI
etiologies from pharyngeal and rectal sources.
Limited comparative data exist on molecular detection
of C. trachomatis from ocular specimens. In an Italian
study reported by Fontana et al. [88], overall sensitivity of
ProbeTec for the detection of C. trachomatiswas 76.5% when
compared to a laboratory-developed PCR assay targeting 16S
rDNA which detected all 34 positive specimens. Two of three
C. trachomatis-positive ocular specimens were detected by
ProbeTec (all three were detected by the assay targeting 16S
rDNA). It was noted that a second laboratory-developed
PCR assay targeting C. trachomatis plasmid DNA detected
28 of 34 overall positive specimens (2 of 3 positive ocular
specimens). A C. trachomatis plasmid DNA deletion rate
of 17.6% was noted in this study. In a study conducted in
Ethiopia, Yang et al. [89] demonstrated that a TMA-based
assay specific solely for C. trachomatis 16S rRNA (ACT; Gen-
Probe) had a detection rate of 59% which was in contrast
to an AMP-derived 28% detection rate. Increased detection
of ocular infection by TMA was independent of active
clinical disease (P ≤ 0.004). These findings extended those
of a previous study [90]. Seven of 15 TMA-positive/AMP-
negative specimens had detectable rRNA subsequent to
a 1 : 10 dilution of the original ocular specimen. Taken
together, these data are relevant because rRNA detection can
mitigate the possibility of C. trachomatis plasmid deletion
[88], low C. trachomatis burden has been demonstrated in
the context of trachoma management [91, 92], and rRNA
concentration far exceeds that of genomic DNA and plasmid
DNA in C. trachomatis [93].
4.4. Trends. Several of the aforementioned findings, plus
considerations related to the detection of other sexually-
transmitted agents [20, 94], may account for increased
utilization of commercial TMA for the detection of C. tra-
chomatis. Surveys of NAAT modalities employed by clinical
laboratories in the United States, conducted by the College
of American Pathologists laboratory accreditation program
[95], have demonstrated an approximate 30% increase in
the utilization of AC2 for C. trachomatis screening from
2003–2010 (Figure 3). Overall participant enrollment in
these surveys has ranged from 525 laboratories in early
2003 to an average of 925 in 2010. Furthermore, a 2004
survey of United States public health laboratories reported
that 87% of respondents performed NAAT for the detection
of C. trachomatis, while less than 40% oﬀered nucleic acid
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Figure 3: Utilization of AMPLICOR (circles), BD ProbeTec
ET (squares), and APTIMA Combo 2 (triangles) platforms for
Chlamydia trachomatis screening in United States laboratories, as
captured by College of American Pathologists proficiency testing
participant summary data collections, 2003–2010. Data are adapted
from [95].
hybridization. Of the laboratories that oﬀered NAAT, 50%
utilized ProbeTec, while 48% performed AC2 [96].
Abbott Laboratories (Des Plaines, Ill, USA) has recently
introduced a testing platform (m2000) to accommodate both
automated specimen processing and real-time multiplex
PCR for the detection of regions of the C. trachomatis cryptic
plasmid and N. gonorrhoeae opacity (Opa) gene. Limit of
the detection was reported at 20 copies of DNA for each
analyte [97].When assessed against AMP and ProbeTec using
residual genital swab material, the m2000 demonstrated
96.3–99.1% concordance of positive C. trachomatis result,
with 98.2–100% concordance of negative result. Urine testing
demonstrated high concordance with AC2 and ProbeTec for
C. trachomatis-negative results (≥98.9%), with 93.7% and
96.8% concordance rates, respectively, for C. trachomatis-
positive results [97]. Levett et al. [72] compared automated
versions of ProbeTec (Viper system) and AC2 (TIGRIS DTS
system) to the m2000 for C. trachomatis urine testing and
reported that sensitivity ranged from 96.9% (m2000) to
99.0% (AC2).
A strain of C. trachomatis with a 377-base pair cryp-
tic plasmid deletion [98] is implicated in the purported
decreased rates of positive C. trachomatis NAAT results
reported in clinical laboratories in Sweden beginning around
2004 [99]. Interestingly, Herrmann et al. reported a propor-
tional rate for this C. trachomatis variant ranging from 20%
to 64% in regions that utilized either m2000 or a commer-
cial real-time PCR system distributed by Roche Molecular
Systems. In contrast, in locales that utilized ProbeTec, the
proportional rate of the C. trachomatis variant ranged from
7% to 19% [99]. Despite these Swedish prevalence data, the
variant has been identified from clinical specimens in only
two neighboring countries [100].
Amidst concern that the m2000 demonstrated poor
utility in the detection of European plasmid mutant C.
trachomatis strains [99, 101], modifications were made to the
Abbott Laboratories primer sets. This reformulated product
(Abbott RealTime CT) was assessed, along with AC2 and
version 2 of the COBAS TaqMan CT test (Roche Molecular
Systems), against a panel of 148 C. trachomatis-positive
urine specimens [102]. Nearly 25% of these specimens
contained the variant C. trachomatis strain. Assay specificity
was nearly 100% for all three systems. Sensitivity of the
COBAS TaqMan CT test (83.0%) was outpaced by analogous
indices for the Abbott Laboratories reformulation (95.3%)
and AC2 (99.3%). A separate study [103] reported that
the reformulated Abbott Laboratories assay yielded slightly
higher sensitivity than ProbeTec.
5. Addressing the Issue of Specificity:
Confirmatory Testing
5.1. Principle andMethods. Eﬀorts to enhance C. trachomatis
NAAT sensitivity theoretically come at the expense of assay
specificity. Overall scenarios that could generate such false-
positive results include the nucleic acid target of interest
being present within other organisms endogenous to a spec-
imen, the detection system generating signal in the absence
of target; iatrogenic contamination, and, clerical errors [29].
In light of this, past literature from the CDC stated that
NAAT assays for C. trachomatis are indeed screening assays
and that an initial positive result should be considered strictly
as presumptive evidence of infection. As such, the CDC
deemed necessary the verification of a positive screen in
cases that could have adverse medical or psychosocial impact
[29]. Furthermore, consideration should be given for the
verification of positive NAAT screens for analyses performed
in low-prevalence STI populations that would render positive
predictive values on the order of 90% or less.
CDC-advocated approaches to additional molecular
testing have been four-fold: (1) testing a second primary
clinical specimen with an assay that utilizes a diﬀerent target
and a diﬀerent format, (2) testing the original primary
clinical specimen with an assay that utilizes a diﬀerent target
and a diﬀerent format, (3) repeating the original test on
the original primary clinical specimen with a competitive
probe, and, (4) repeating the original test on the original
specimen. Laboratories that choose commercial nucleic acid
hybridization as the method of choice for the detection of C.
trachomatis can utilize a direct and competitive probe-based
nucleic acid hybridization technology [39, 40]. However, it is
not advisable to utilize less-sensitive signal amplification or
nucleic acid hybridization technologies to confirm a positive
screen derived by NAAT [29]. The method advocated first
and foremost may not be a reality in certain healthcare
environments or in the public health sector due, in part, to
the diﬃculty in successfully contacting a patient to return
for specimen recollection.
5.2. Repeat Testing. Recent literature suggests that the para-
digm of repeat testing may introduce diﬃculties to the
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final interpretation of NAAT results. Culler et al. [104]
reported that 5.3% of initially positive C. trachomatis screens
yielded by ProbeTec failed to duplicate results upon repeat
testing. Castriciano et al. [105] demonstrated that 93.1%
of initially positive C. trachomatis screens derived by AMP
remained positive upon repeat testing of original lysates.
This value dropped to 85.3% upon testing a second nucleic
acid extraction. Schachter et al. [106] reported that only
83.8% of positive C. trachomatis screens derived by ProbeTec
retained positive status upon repeat testing. This value
was elevated to 92.5% upon a second repeat ProbeTec
assay. In contrast, 96.7% and 97.7% of AMP and AC2
screens, respectively, generated a positive result upon repeat
testing. This phenomenon has also been noted in molecular
detection of N. gonorrhoeae. In the study of Culler et al.
[104], 10.7% of positive N. gonorrhoeae screens obtained
via ProbeTec failed to retain positive status upon repeat
testing. Usingmultiple specimen sources,Moncada et al. [87]
demonstrated that 89.3% of positive N. gonorrhoeae screens
derived by ProbeTec retained positive status by repeat testing.
This value increased to 92.4% and 93.1% upon a second and
third repeat test, respectively. In contrast, repeat testing of
positive screens initially derived by AMP and AC2 retained
positive status 95.7% and 96.4% of the time, respectively.
5.3. Low-Positive Screens. A further delineation of positive
NAAT screens reveals an additional conundrum in terms of
a role for confirmatory testing in final result interpretation.
80.8% of low-positive C. trachomatis screens derived from
ProbeTec (defined as signal detection method other than
acceleration (MOTA) scores from 2000 to 9999) remained
positive upon repeat testing, while only 33.3% of N.
gonorrhoeae screens retained the positive status [104]. This
paradigm may be of greater consideration when studying a
highly sensitive assay such as AC2. Two reports [107, 108]
documented positive status retention rates of 42–63% for
low-positive C. trachomatis screens (defined as relative light
unit values between 100,000 and 1,000,000). In contrast,
Dunham et al. [107] determined that only 31.6% of low-
positive N. gonorrhoeae screens retested positive. In a high-
prevalence population for both C. trachomatis and N. gonor-
rhoeae, 71.3% and 58.5% of low-positive C. trachomatis and
N. gonorrhoeae screens, respectively, yielded positive results
upon repeat testing [109]. No significant diﬀerence existed
between the percentages of low-positive C. trachomatis and
N. gonorrhoeae screens that remained positive by repeat
testing (P = 0.10). Despite the fact that repeat testing
potentiates result interpretation challenges, this low-positive
phenomenon, even under the auspices of AC2, presents itself
in just 2% of C. trachomatis screens and less than 0.1% of N.
gonorrhoeae screens performed [107, 109].
5.4. Alternative Target Testing. A fourth CDC-advocated
practice, the utilization of an alternative NAAT system or
platform, has met with variable success. Schachter et al.
[110] reported that while AC2 confirmed 96.9% of positive
ProbeTec screens (95.4% in urine specimens, 98.6% in
genital swab specimens), ProbeTec was able to confirm
only 82.0% of positive C. trachomatis screens derived from
AC2 (85.3% in urine specimens, 78.9% in genital swab
specimens). Chernesky et al. [64] reported 69.6% and 80.3%
rates of confirmation of positive AC2 urine C. trachomatis
screens by AMP and ProbeTec, respectively. Analogous rates
for confirmation of positive AC2 endocervical C. trachomatis
screens were 62.9% and 70.9%. In contrast, 98–100% of
positive urine or genital swab C. trachomatis screens yielded
by ProbeTec or AMP were confirmed by AC2. In a small
subset of specimens that tested equivocal for C. trachomatis
via AMP or yielded a discrepant result in the context of a
combined reference standard, Peterson et al. [111] reported
that only 23.1% of specimens yielded a concordant result
when subjected to separate PCR assays targeting diﬀerent
sequences. A C. trachomatis concordance rate of 82.1%
was demonstrated from initial nucleic acid extracts when
commercial ligase chain reaction-positive urine screens were
tested by AMP [105]. These data further substantiate diﬀer-
ences in analytical sensitivity of these NAATmodalities. Sim-
ilar findings were derived from N. gonorrhoeae confirmatory
testing. Moncada et al. [87] demonstrated that percentages
of positive N. gonorrhoeae screens derived by ProbeTec that
were confirmed by AC2 and AMP analysis were 85.0%
and 78.4%, respectively, and that 84.6% of positive AC2
N. gonorrhoeae screens were confirmed by ProbeTec. Yet
when similar analysis was restricted to male urine specimens,
nearly all positive N. gonorrhoeae screens, independent of
modality, were confirmed by secondary NAAT.
APTIMA CT and GC assays have allowed for detailed
analysis of the CDC-advocated practice of confirmatory
testing using an alternative nucleic acid target. Sensitivity
and specificity values greater than 96% were demonstrated
for these assays in a multicenter study of MSM using both
urethral swabs and urine specimens [112]. Boyadzhyan et al.
[32] reported complete concordance of AC2 C. trachomatis
and APTIMA CT assay results on 253 urine specimens
and 422 genital swab specimens collected from either
gender. Schachter and colleagues [106, 110] demonstrated
that the APTIMA CT assay confirmed 98-99% of positive
AC2 screens, with just slight diﬀerences noted between
concordance values from urine and genital swab specimens
[106]. Comparable data have been reported with respect
to N. gonorrhoeae confirmatory testing. Golden et al. [113]
reported that 258 of 265 positive N. gonorrhoeae screens
of female urine or endocervical specimens derived by AC2
also yielded a positive APTIMA GC assay result. Moncada
et al. [87] demonstrated that 95.7% of combined gender
specimens initially screening positive by AC2 yielded a
positive APTIMA GC result.
5.5. Comparisons of Repeat Testing to Alternative Target Con-
firmation. Data from a five-state United States moderate-
prevalence chlamydia population (cumulative C. trachomatis
infection rate of 312.7 per 100,000 population) revealed
that repeat testing versus performance of the APTIMA CT
assay on AC2-positive C. trachomatis screens demonstrated
95% concordance of the final result [114]. Schachter et al.
[106] utilized a moderate-prevalence California population
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(336.7 cases per 100,000 population) to demonstrate an
84–98% rate of initial AC2 screen confirmation by repeat
testing and a potentially elevated rate (89–99%) of initially
positive screens confirmed by secondary NAAT. In a high-
prevalence population (684.0 cases per 100,000 population),
significantly more low-positive C. trachomatis screens were
confirmed by the APTIMA CT assay than by duplicate
repeat testing [109]. However, these authors noted that
utilization of alternative target TMA for confirmation raised
overall AC2 C. trachomatis positive predictive value only
1.8% over that derived from repeat testing. Similar findings
characterized N. gonorrhoeae screen verification algorithms.
Zanto et al. [114] demonstrated 90% concordance in final
N. gonorrhoeae AC2 result derived by repeat testing versus
alternative target TMA. Moncada et al. [87] summarized
their side-by-side comparison of the two advocated methods
by noting that 89–96% of specimens positive by initial NAAT
were confirmed by repeat testing and that 85–98% of initial
screening results were confirmed via secondary NAAT. In
a high-prevalence gonorrhea population (265.9 cases per
100,000 population), confirmatory testing via the APTIMA
GC assay demonstrated only a 5% increase in the rate of AC2
low-positive result retention [109].
6. Test of Cure
Due to very high microbial cure rates exhibited by azithro-
mycin and doxycycline in a recent meta-analysis [115],
the CDC does not advocate C. trachomatis test-of-cure
analysis in males or in nongravid females, unless therapeutic
compliance is questioned, symptoms persist, or reinfection is
suspected [116]. Workowski et al. [117] utilized an in-house
PCR to demonstrate a reduction in rate of endocervical
detection of C. trachomatis from 50% immediately following
completion of doxycycline therapy to 15% seven days later.
Nucleic acid was not detected at the two-week interval.
Gaydos et al. [118] reported greater C. trachomatis-specific
nucleic acid recovery rates for commercial ligase chain
reaction (37–73%, interval dependent) over those of AMP
(21–40% for similar intervals) within the first six days
following the completion of therapy.
In contrast, an in-house PCR detected C. trachomatis
nucleic acid from 25% of endocervical swabs collected three
weeks after the completion of therapy [119]. In the same
study, nucleic acid sequence-based amplification, an RNA
amplification technology, yielded a C. trachomatis detection
rate of only 6.7% and 8.0% from urine and endocervical
specimens, respectively, one week after the completion of
therapy. Comparator percentages were 26.7% and 84.0% for
the PCR. Bianchi et al. [120] subjected post treatment urine
specimens to AMP and the Gen-Probe first generation TMA
assay. Kinetics of both systems was essentially equivalent in
females, demonstrating full clearance within six days. Similar
results were generated in a smaller sampling of males.
According to recently published CDC recommendations
[116], test-of-cure protocols are unnecessary for patients
who have completed antimicrobial therapy for N. gonor-
rhoeae infection because multiple lines of therapy have
proven eﬃcacious [121]. Exceptions to this paradigm are
in the minority and are potentially linked to increasing
resistance of N. gonorrhoeae to fluoroquinolone agents [122,
123]. However, high prevalence of N. gonorrhoeae infection
exists in patients who have had gonorrhea in the preceding
months [124]. These data imply that the detection of N.
gonorrhoeae post-treatment may actually be reflective of
reinfection rather than treatment failure. If symptoms persist
in patients following the completion of therapy, clinicians
may consider re-testing patients, via culture modalities,
for the ultimate purposes of antimicrobial susceptibility
testing. This approach is hypothetically far more eﬃcacious
in the management of N. gonorrhoeae infection than in C.
trachomatis infection because of stark diﬀerences in culture
sensitivity [28].
A paucity of studies has characterized an auxiliary role
for NAAT in gonorrhea test-of-cure. For example, Hanks
et al. [125] demonstrated that nucleic acid hybridization was
unable to generate N. gonorrhoeae signal from genital and
urine specimens of patients between six and eleven days
post-completion of antimicrobial therapy for N. gonorrhoeae
infection. Bachmann et al. [126], utilizing a commercial
ligase chain reaction, reported the median time to a negative
N. gonorrhoeae urine assay being one day for males and
two days for females upon completion of therapy. Among
females, the mean clearance time proved greater for genital
specimens (2.8 days) than for urine specimens (1.7 days; P =
0.008). An intermittent shedding phenomenon was observed
in 15% of males and 25% of females during the three-
week follow-up period. Women who shed N. gonorrhoeae
nucleic acid intermittently were twice as likely to have a
genital specimen yield detectable N. gonorrhoeae compared
to a urine specimen. In one female patient, such detection
occurred 19 days after the completion of therapy.
7. Utility in Medicolegal Settings
The shorter length of the vagina in prepubescent girls,
combined with its columnar epithelial cell lining and alkaline
environment, can predispose this population to infection
with sexually transmitted agents including C. trachomatis
[127]. The extrapolation of C. trachomatis detection in
children beyond the neonatal period to sexual abuse [116]
has some limitations. It has been estimated that 20% of
infants born to women with active C. trachomatis infection
can acquire the infection in rectal and vaginal sites [128].
Persistence of the organism acquired in perinatal fashionmay
last 2-3 years [129]. Moreover, retrospective chart reviews
[130–133], subcomponents of which utilized C. trachomatis
NAAT, have outlined very low incidence of C. trachomatis
detection (0.5–3.1%) in the context of child sexual abuse.
Schachter et al. [79], within a significant at-risk population
for STI acquisition, reported lower C. trachomatis detection
rates from oropharyngeal and rectal sites (0.8% and 6.1%,
resp.) than those for N. gonorrhoeae. Taken together, it must
be noted that the positive predictive value of even very highly
specific NAAT screens can be compromised by low disease
prevalence in a given setting [134].
Largely as a result, it has been a long-standing axiom that
C. trachomatis cultivation has more validity in medicolegal
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Table 3: Recommended diagnostic modalities and specimen sources for evaluation of child sexual abuse victims. Data are adapted from
[116].
Diagnostic modality
Recommended specimen sources for STI etiology
Chlamydia trachomatis Neisseria gonorrhoeae
Female Male Female Male
Oropharynx Oropharynx
Anus Anus Anus Anus
Culture Urethra
Urethral discharge Urethral discharge
Vagina Vagina
NAAT†
Urine Urine
Vagina Vagina
†
Nucleic acid amplification testing.
proceedings than results derived from NAAT [135]. Despite
this, in a limited sexual abuse victim dataset, Matthews-
Greer et al. [136] described 11 instances of C. trachomatis
culture data being corroborated by a positive PCR result.
Two rectal specimens were culture positive/PCR negative,
while one rectal and three female genital swabs yielded
culture-negative/PCR-positive results. Girardet et al. [137]
reported that 18 of 215 (8.4%) possible pediatric sexual abuse
victims generated a positive NAAT for C. trachomatis from
a noninvasive urine specimen. Cultures for C. trachomatis
were positive in only 44% of instances. Kellogg et al. [138]
reported 11–18% agreement between C. trachomatis culture
results and those derived from ligase chain reaction or PCR
performance on urine and vaginal specimens collected from
girls who reported abusive sexual contact. Among 485 girls
being evaluated for sexual abuse, sensitivity of urine C. tra-
chomatisNAAT was 100% when compared to vaginal culture
[139]. Eight additional patients yielded positive urine C.
trachomatisNAAT in the face of negative culture (P = 0.018).
Interestingly, in 2001 Hammerschlag [134] stated that
the advancement of NAAT evidence in courts of law was
hindered by the paucity of appropriate commercially avail-
able confirmatory assays. With the advent of the APTIMA
CT assay and defined performance characteristics [32, 112],
perhaps this scenario warrants additional consideration.
CDC recommendations have varied on this topic within the
past five years. 2006 recommendations for the management
of STI [140] stated that NAAT might be a viable alternative
in the detection of C. trachomatis if culture systems for the
organism are unavailable and if a method of confirmation is
available. Noted means of confirmation included secondary
FDA-cleared NAAT targeting a diﬀerent sequence than the
primary screening method [140]. This nonculture option for
the detection was not advocated for laboratory diagnosis of
N. gonorrhoeae. Black et al. [139] remarked that urine NAAT
methodologies (with subsequent confirmatory testing) are
adequate as a new forensic standard in children suspected of
being sexual abuse victims. The recently published guidelines
[116] place primary focus on standardized anal (both
genders), urethral discharge (males), and vaginal culture
techniques for both C. trachomatis and N. gonorrhoeae
(Table 3). The paucity of specimen source options available
for C. trachomatis culture is related to low source-specific
organism prevalence rates and the paradigm of chlamydial
persistence following perinatal acquisition. NAAT for C.
trachomatis and N. gonorrhoeae from vaginal and urine
specimens is recommended in girls as an alternative to cul-
ture. Furthermore, in the context of sexual assault in adults
and adolescents, the latest recommendations call for the
performance of FDA-cleared NAAT for either C. trachomatis
or N. gonorrhoeae upon initial examination. The topic of
STI detection in the context of medicolegal testing has been
reviewed extensively by Hammerschlag and Guille´n [141].
8. Conclusions
Independent of specimen transport conditions, sensitiv-
ity of C. trachomatis culture is greatly inferior to those
of amplified molecular methods that have since largely
replaced signal amplification and nucleic acid hybridization
assays. Because molecular-based testing for N. gonorrhoeae
is simultaneously provided within commercial molecular
assays for C. trachomatis, many laboratories subsequently
forego sole reliance upon culture methods for N. gonor-
rhoeae detection from urine and genital sources. Sensitivity
diﬀerences between commercial PCR, SDA, and TMA have
been delineated in the literature, both in clinical and in vitro
settings. The aforementioned specimen types are applicable
to AC2, with the addition of vaginal swab and gynecological
specimens (Table 4). A limited role for C. trachomatis culture
may be seen in medicolegal settings or for cultivation from
specimen sources that are not indicated for FDA-approved
NAAT. However, studies have emerged advocating a highly
sensitive NAAT modality, such as commercial TMA, to
augment culture methodology for accurate detection of C.
trachomatis from extragenital sites.
Validity of results generated by highly sensitive modal-
ities has been addressed with a variety of confirmatory
testing algorithms. Limitations to follow-up testing include
clinicians not routinely providing two specimens for eval-
uation and the prohibitive expense for some laboratories
to either modify an existing molecular assay to target a
diﬀerent nucleic acid sequence or validate secondary NAAT.
Even when NAAT is utilized as a means of confirmation,
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Table 4: United states food and drug administration-approved specimen sources for commercially available Chlamydia trachomatis nucleic
acid amplification testing. Data are derived from [50–52].
Modality Symptomatic female Symptomatic male Asymptomatic female Asymptomatic male
AMPLICOR
Endocervix Urethra Endocervix Urethra
Urine Urine Urine Urine
BD ProbeTec ET
Endocervix Urethra Endocervix Urethra
Urine Urine Urine Urine
APTIMA Combo 2
Endocervix Urethra Endocervix Urethra
Urine Urine Urine Urine
Vaginaa Vaginaa
Gynecology Examb Gynecology Examb
Vaginac
aClinician collected.
bCollected in PreservCyt Solution; processed with ThinPrep 2000 system (Cytyc Corporation, Marlborough, Mass, USA).
cPatient collected.
diﬀerences in performance characteristics of these assays,
deficiencies in result reproducibility for a given specimen
using the same testing modality, and potential diﬀerences
in sensitivity related to heterologous specimen collection
media/transport devices have been reported [106]. Even
when repeat testing is factored into this paradigm, additional
generated data may be diﬃcult to interpret, especially when
considering the extremely high rates of sensitivity and
specificity already inherent to these screening assays. It must
be kept in mind that CDC recommendations related to C.
trachomatis screening diagnostics have not been updated
since 2002 [29]. On the basis of the discussion provided in
Section 5 of this review, any subsequent revision may result
in significant changes related to this paradigm.
While currently not widely accepted as medicolegal
evidence due to concerns over specificity, admission of NAAT
results may eventually become standard practice in courts of
law. Prominent acceptance of alternative target confirmatory
testing may have to play a significant role for this to occur,
particularly with a highly sensitive method such as com-
mercial TMA. Viable test-of-cure options are not extensive
in the setting of chlamydia due to meager sensitivity of C.
trachomatis culture. At the same time, amplified molecular
test-of-cure protocols are deemed unnecessary in a majority
of settings due to eﬃcacious therapeutic regimens. Auxiliary
studies utilizing NAAT demonstrate microbiological cure
approximately 7–14 days after therapy, yet investigations in
this vein using latest-generation commercial TMA would be
compelling.
Chlamydia prevalence has experienced a significant
upswing in the United States over the past 15 years. Clinical
presentation of male urethritis exhibits overlap with that of
nongonococcal urethritis. In females, symptoms of chlamy-
dia can resemble those of gonorrhea or trichomoniasis.
These data predicate the importance of laboratory detection
of C. trachomatis. Poor C. trachomatis culture sensitivity
signifies the importance of nonculture diagnostic modalities.
With respect to the utilization of the rapid, nonamplification
methods for C. trachomatis detection, one must be cautious
to the actual “point-of-care” benefit therein, as many studies
have proven these methods to have much lower analytical
sensitivity than NAAT. Consequently, as nucleic acid-based
diagnostic assays continue to improve, a greater presence for
such testing needs to be established in both small- and large-
scale clinical laboratory settings.
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